ChromaDex's proprietary healthy aging ingredient Niagen will be added to multi-ingredient Designs for Health formulas.
The Company says that Niagen is the world's first and only FDA-safety reviewed and patented form of nicotinamide riboside.
The new products will be available exclusively through the Company's extensive HCP network.
The Niagen inclusive formulas will be available to healthcare practitioners through the Designs for Health customers throughout the U.S., Canada, and Australia.
In October, ChromaDex announced findings from a clinical study of Niagen ingredient (nicotinamide riboside, NR) in patients with ataxia-telangiectasia (AT).
AT is a rare, inherited neurodegenerative disorder characterized by premature aging, cerebellar degeneration, immunodeficiency, and cancer predisposition.
The study found that supplementation with NR improved ataxia scores and increased immunoglobulins, or antibodies, in the immune-compromised patients under 18 years.
Price Action: CDXC shares are up 9.06% at $3.01 during the market session on the last check Thursday.
See more from Benzinga
© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.